Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.61 |
| ▸ | REN | P00797 | 3/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591156 | 1.00 | CCR1 (0.61) | CCR1RENLAP3ANPEPRNPEP | |
| SCHEMBL4068003 | 0.94 | CCR1 (0.58) | CCR1ALDH1A1CYP3A4MMP8 | |
| SCHEMBL4071980 | 0.92 | CCR1 (0.54) | CCR1REN | |
| SCHEMBL4067803 | 0.90 | CCR1 (0.56) | CCR1ANPEPALDH1A1CYP3A4 | |
| SCHEMBL4062733 | 0.89 | CCR1 (0.51) | CCR1RENALDH1A1 | |
| SCHEMBL6832278 | 0.89 | CCR1 (0.58) | CCR1RENLAP3ANPEPRNPEP | |
| SCHEMBL4064045 | 0.89 | CCR1 (0.61) | CCR1RENLAP3ANPEPRNPEP | |
| SCHEMBL6169670 | 0.89 | CCR1 (0.61) | CCR1RENLAP3ANPEPRNPEP | |
| SCHEMBL4064275 | 0.89 | CCR1 (0.58) | CCR1RENLAP3ANPEPRNPEP | |
| SCHEMBL4068540 | 0.89 | CCR1 (0.51) | CCR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004039375-A1 | METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | CCR1 1/4885REN 3519/4885LAP3 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.